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Objectives. To compare secondary intervention rate, aneurysm-related mortality and all-cause mortality for patients
receiving elective endovascular aneurysm repair (EVAR) for large abdominal aortic aneurysms with different commercially
available endografts.
Design, materials & methods. In the EVAR 1 and 2 multi-centre trials, the principal endografts used were Zenith and
Talent and these are compared in 505 patients from EVAR 1 and 143 patients from EVAR 2 followed-up for an average of
3.8 years until 31st December 2005. Outcomes were analysed by Cox proportional hazards regression, with adjustments
for potential confounding risk factors and centre. Gore/Excluder graft outcomes also are reported.
Results. Across the two trials the secondary intervention rates were 7.0 and 9.4 per 100 patient years for Zenith and
Talent grafts respectively, adjusted hazard ratio 0.77 [95%CI 0.52e1.12]. Aneurysm-related mortality was 1.2 and 1.4
per 100 patient years for Zenith and Talent grafts respectively, adjusted hazard ratio 0.90 [95%CI 0.37e2.19]. All-cause
mortality was 8.5 and 10.3 per 100 patient years for Zenith and Talent grafts respectively, adjusted hazard ratio 0.81
[95%CI 0.58e1.14]. The direction of all results was similar when the two trials were analysed separately.
Conclusion. There was no significant difference in the performance of the two endografts but the direction of results was
slightly in favour of patients with Zenith (versus Talent) endografts.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The pioneers of endovascular aortic aneurysm repair
used ‘‘home-made’’ endografts.1,2 The possibilities of
this new, minimally invasive approach to repairing
abdominal aortic aneurysms (AAAs) soon attracted
commercial attention. The early commercial devices
encountered a variety of problems and several have
been voluntarily withdrawn from the market. Regula-
tory authorities in Europe and the USA still maintain
a close watch on the performance of contemporary en-
dografts and from time to time have issued alerts for
specific devices.3,4 By now the technology for contem-
porary bifurcated devices is relatively stable. Today
there are at least 5 different companies offering bifur-
cated endografts of different design for infra-renal
AAA repair (endovascular aneurysm repair or
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From the perspective of patient, clinician and regula-
tory authority there is a need to know whether any of the
currently available devices are superior to their compet-
itors. It is clear that randomised trials comparing devices
would be challenging given their different anatomical
requirements. Some comparative data for contemporary
EVAR devices from registries or large volume centre se-
ries are becoming available.5e7 The registries suffer from
voluntary participation and incomplete reporting that
could make comparative data unreliable. The large vol-
ume centre series are retrospective and difficult to adjust
for relevant confounders. Two multi-centre randomised
trials of open surgical repair versus EVAR have pub-
lished mid-term results.8,9 In these trials there has been
close scrutiny of endograft performance with regular
surveillance by CTscanning and comprehensive report-
ing of further interventions, complications such as graft
migration, graft limb thrombosis and endoleaks: in the
EVAR 1 trial, secondary interventions had been per-
formed in 20% of patients undergoing elective EVAR
by 4 years of follow-up.8 This reporting comes fromar Surgery. Published by Elsevier Ltd. All rights reserved.
282 The EVAR Trial Participantsthe individual trial centres and, for the UK EVAR trials,
a programme to evaluate all CTscans in a standard man-
ner at a core laboratory has started, to provide rigorous
reporting of graft migration and endoleaks.
From the patient and health economic perspectives
the need for further intervention is particularly
important. The two principal EVAR devices used in
the EVAR 1 trial were Zenith (Cook) and Talent
(Medtronic). Excluder (Gore) was used in only about
7% of patients. In this first report to assess device per-
formance, the mid-term secondary intervention rate
(including graft ruptures and conversions to open
repair) and mortality (all-cause and AAA-related)
associated with use of the two principal devices in
the EVAR trials 1 and 210 are compared and the
results for the Excluder device are reported.
Materials and Methods
The detailed methodology for the EVAR trials has
been described previously.11 In brief, patients of either
gender who were at least 60 years of age with an AAA
measuring 5.5 cm or greater by CT scan were assessed
for anatomical suitability for EVAR. Suitable patients
were offered entry into EVAR Trial 1 if they were con-
sidered fit enough to have open AAA repair and con-
senting patients were randomised to receive either
EVAR or open repair. Patients who were considered
unfit for open repair were offered entry into EVAR
Trial 2 which randomised patients to either EVAR or
no intervention. In both trials, the device used was
selected by the participating centre, and centralised
National Health Service funding reimbursed the
cost of all devices. Planned recruitment closed at
the end of December 2003 and mid-term results
have been published on these patients.8,10 However,
randomisation into both trials continued until the
publication and dissemination of early trial results at
the end of August 2004 and during this additional
period the number of patients randomised increased
to 1252 in EVAR Trial 1 and 404 in EVAR 2. All
patients were followed up for death, through the
Office for National Statistics (ONS), until 31st Decem-
ber 2005 (minimum follow-up 1.3 years, mean 3.8
years ignoring censoring by death). An endpoints
committee reviewed the causes of death, to ascertain
aneurysm-related mortality as accurately as possible.
The reporting of re-interventions and graft complica-
tions was based upon case record form data sent by
the trialists at each of the participating EVAR trial
centres.
The aim of this study was to compare secondary in-
tervention rate, mid-term AAA-related and all-cause
Eur J Vasc Endovasc Surg Vol 34, September 2007mortality of the principal grafts used in each EVAR
trial. The data from each trial were analysed sepa-
rately, but device comparisons also were combined
across the trials to increase power.
Analyses were restricted to those patients who re-
ceived EVAR within their EVAR randomised group.
Thus, in the EVAR arm of EVAR Trial 1, there were
598 elective EVAR procedures using the following
devices: 318 Zenith (Cook), 187 Talent (Medtronic),
37 Excluder (Gore) and 56 others. For the comparison
of Zenith and Talent devices, the 505 patients had
a median follow-up of 2.87 years (prior to death or
end of follow-up). In the EVAR arm of EVAR Trial 2,
174 EVAR devices were implanted electively: 109
Zenith (Cook), 34 Talent (Medtronic), 10 Excluder
(Gore) and 21 others. For the comparison of Zenith
and Talent devices the 143 patients had a median
follow-up of 2.11 years (prior to death or end of
follow-up).
Statistical analysis
The analyses were conducted according to a plan
drawn up before inspecting the device-specific
data. Patients recruited into the EVAR trials up to
August 2004 and followed up to 31 December 2005,
randomised to EVAR and electively receiving a Ze-
nith or Talent device, were included in the primary
analyses. It was decided that there were too few Ex-
cluder devices for formal statistical comparison. Sep-
arate analyses of the EVAR 1 and EVAR 2 trials were
performed; device differences were then combined in
analyses stratified by trial. Baseline characteristics
and peri-operative variables in patients receiving dif-
ferent devices were compared using t-tests or chi-
squared tests for continuous and categorical vari-
ables respectively. All-cause mortality, AAA-related
mortality (including all deaths within 30 days of
AAA surgery; censoring other causes of death) and
secondary intervention (time to first re-intervention,
conversion to open surgery, or graft rupture; censor-
ing deaths) were analysed using Cox proportional
hazards regression. Adjustments for pre-defined sets
of baseline variables in estimating the device differ-
ences, expressed as hazard ratios, were made using
propensity score analyses.12 Adjustment was for age,
sex, initial AAA diameter, FEV1, log(creatinine), statin
use, of graft (uni-iliac or bifurcated), aneurysm top
neck diameter, aneurysm bottom neck diameter, aneu-
rysm neck length, right common iliac diameter, left
common iliac diameter and calendar year of operation.
These propensity score adjustments correct for imbal-
ances in characteristics between the patient groups re-
ceiving different devices, which can be employed
283A Comparison of Zenith and Talent Grafts in the UK EVAR Trialswhen there are many covariates and only limited num-
bers of events.13 Crude and adjusted results are re-
ported with the adjusted results regarded as the
primary analysis. Further adjustment for body mass
index, smoking status, systolic blood pressure and se-
rum cholesterol made little difference. Additional ad-
justment for clinical centre as a random effect14 was
always non-significant ( p> 0.2) and made no material
difference to the results. Kaplan-Meier plots stratified
by device are based on the adjusted Cox regression
estimates.Results
Outcomes in EVAR 1
Baseline demographic characteristics at randomisation
and descriptive peri-operative information for patients
receiving Zenith, Talent and Excluder devices in EVAR
1 are shown in Table 1, together with a formal compar-
ison between patients with Zenith and Talent devices.
There were too few Excluder devices for useful statisti-
cal comparison. Overall, the baseline characteristics of
the patients used for this analysis were similar to thoseTable 1. Baseline demographic and peri-operative variables for patients in EVAR 1 with elective endovascular repair by device type
Zenith
(N¼ 318)
Talent
(N¼ 187)
P-value comparing
Zenith and Talent
Excluder
(N¼ 37)
Mean (s.d.) Mean (s.d.) Student’s t-test Mean (s.d.)
Continuous variables
Age at randomisation (years) 74.0 (6.0) 74.1 (6.1) 0.80 73.4 (6.0)
AAA diameter (cm) 6.4 (0.9) 6.4 (0.8) 0.80 6.4 (0.7)
FEV1 (L) 2.2 (0.7) 2.0 (0.7) 0.0002 2.1 (0.7)
Creatinine, median [IQR] (mmol/L)
(Median used as data skewed)
102 [91e117] 102 [91e121] 0.07a 97 [86e112]
AAA top neck diameter (cm) 2.4 (0.3) 2.4 (0.3) 0.86 2.2 (0.3)
AAA lower neck diameter (cm) 2.5 (0.4) 2.5 (0.4) 0.34 2.3 (0.3)
AAA neck length (cm) 2.8 (1.2) 2.8 (1.1) 0.98 2.7 (1.1)
Right common iliac diameter (cm) 1.6 (0.7) 1.7 (0.7) 0.49 1.4 (0.4)
Left common iliac diameter (cm) 1.6 (0.6) 1.5 (0.4) 0.02 1.4 (0.4)
Body mass index (kg/m2) 26.8 (4.8) 26.6 (4.6) 0.62 25.0 (3.8)
Systolic blood pressure (mm Hg) 148.3 (22.3) 147.8 (21.2) 0.83 143.0 (21.2)
Serum cholesterol (mmol/L) 5.0 (1.2) 5.2 (1.3) 0.11 5.3 (1.2)
Calendar date of operation
(years since 01.01.1998)
4.7 (1.3) 4.4 (1.4) 0.002 4.2 (1.4)
No. of patients (%) No. of patients (%) Chi-squared test No. of patients (%)
Categorical variables
Sex
Number of men 289 (90.9%) 168 (89.8%) 0.70 31 (83.8%)
Statin used 110 (34.9%) 68 (36.4%) 0.74 12 (33.3%)
Smoking
Current 67 (21.1%) 34 (18.2%) 0.36 12 (32.4%)
Past 216 (67.9%) 129 (69.0%) 24 (64.9%)
Never 35 (11.0%) 24 (12.8%) 1 (2.7%)
Mean (s.d) Mean (s.d) Student’s t-test Mean (s.d)
Peri-operative continuous variables
Blood loss (mls) 102 (388) 130 (430) 0.46 111 (252)
Contrast agent (mls) 204 (105) 196 (98) 0.48 172 (113)
Length of operation (mins) 194 (70) 170 (49) 0.0001 163 (51)
ITUþHDU usage (days) 1.5 (4.0) 0.9 (3.6) 0.08 0.4 (0.6)
Length hospital stay (days) 8.6 (14.4) 11.3 (20.0) 0.08 9.0 (9.2)
No. of patients (%) No. of patients (%) Chi-squared test No. of patients (%)
Peri-operative categorical variables
Graft shape
Uni-iliac 20 (6.4%) 15 (8.4%) 0.82 0 (0%)
Bi-iliac/bi-fem 291 (93.6%) 163 (91.6%) 36 (100%)
Anaesthesia
General 241 (77%) 138 (76%) 0.90 30 (81%)
Epidural/local 73 (23%) 43 (24%) 7 (19%)
a Student’s t-test based upon log-transformed creatinine measurements.
FEV1¼ Forced expiratory volume in 1 sec, ITU¼ Intensive Care Unit, HDU¼High Dependency Unit.
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selected by the participating centre and therefore there
were some differences in baseline characteristics be-
tween the patients receiving Zenith and Talent devices,
particularly for lung function as assessed by forced ex-
piratory volume in 1 sec (FEV1). Zenith devices were,
on average, implanted at a later time during the course
of the trials than the Talent devices and the Excluder de-
vices were implanted the earliest. There were some dif-
ferences between the devices in terms of peri-operative
variables, with Zenith devices requiring more operat-
ing time in theatre than the Talent devices. Although
there was a shorter hospital stay for the Zenith devices,
there appeared to be a greater need for ITU/HDU beds
than for the Talent devices.
Secondary interventions per 100 patient-years were
non-significantly lower in patients receiving Zenith
grafts at 6.4 versus 8.6 for patients with Talent grafts
and this non-significant difference remained after
adjustment for baseline covariates (Table 2). The under-
lying reasons for secondary interventions are shown in
Table 3. Graft thrombosis appeared to be a more com-
mon problem in patients with Zenith grafts whilst
migration and type I endoleak were more common in
patients with Talent grafts. Overall, fewer secondary
interventions were reported for patients with Zenith
grafts (17.6%) versus patients with Talent grafts
(22.5%). The crude AAA-related and all-cause mortal-
ities appeared lower for Zenith patients than for Talent
patients. However, these differences were diminished
after adjustment for differences in baseline covariates
(Table 2). Adjusted survival curves for secondary inter-
ventions and mortality are shown in Figs. 1 and 2
respectively. For patients with Excluder grafts, therewere no operative or AAA-related deaths and the all-
cause mortality was 3.7 [95% CI 1.2e8.7] per 100
person-years, somewhat lower than for the Zenith
and Talent device groups. There were 4 re-interven-
tions for the Excluder group, one for graft rupture,
two for type 2 endoleak and one for exploration of
a false aneurysm.
Outcomes in EVAR 2
The baseline characteristics and peri-operative vari-
ables for patients receiving Zenith and Talent grafts
only are shown in Table 4 and there appeared to be little
difference between this cohort and that reported in the
mid-term EVAR 2 analyses10 although the use of statins
has increased slightly. Too few patients received Ex-
cluder grafts (n¼ 10) to justify reporting of either base-
line characteristics or outcomes. There were few clear
differences but a greater proportion of the Talent de-
vices were aorto-uni-iliac, and this may be explained
by the slightly larger mean right common iliac diameter
in the Talent group. There was some evidence to sug-
gest that the Zenith group were slightly older than the
Talent group and that fewer patients were being treated
with statins in the Zenith group than the Talent group.
There were also more current smokers in the Zenith
group. There was little difference in peri-operative vari-
ables between the devices.
Secondary interventions per 100 person-years ap-
peared lower for the Zenith grafts at 9.6 versus 15.1
for patients with Talent grafts, although this differ-
ence was non-significant even after adjustment for
baseline covariates (Table 2). The underlying reasons
for secondary intervention are shown in Table 3; againTable 2. Cox regression analysis for secondary intervention, AAA-related mortality and all-cause mortality for patients with Zenith
versus Talent devices in EVAR 1 and EVAR 2 separately
EVAR trial 1 EVAR trial 2
No. events/No. patients
(Events per 100 person-years)
Hazard ratio (95% CI) [p-value] No. events/No. patients
(Events per 100 person-years)
Hazard ratio (95% CI) [p-value]
Zenith (N¼ 318) Talent (N¼ 187) Crude Adjusteda Zenith (N¼ 109) Talent (N¼ 34) Crude Adjusteda
Secondary intervention
56/318 (6.4) 42/187 (8.6) 0.77 (0.52e1.15)
[0.205]
0.79 (0.51e1.21)
[0.273]
21/109 (9.6) 10/34 (15.1) 0.68 (0.31e1.47)
[0.325]
0.69 (0.29e1.62)
[0.391]
AAA-related mortality
8/318 (0.8) 6/187 (1.0) 0.77 (0.27e2.23)
[0.636]
0.88 (0.29e2.65)
[0.817]
7/109 (2.8) 3/34 (4.0) 0.69 (0.18e2.66)
[0.589]
0.94 (0.21e4.27)
[0.939]
All-cause mortality
58/318 (5.9) 50/187 (8.6) 0.70 (0.48e1.02)
[0.062]
0.79 (0.53e1.19)
[0.263]
46/109 (18.5) 18/34 (23.9) 0.83 (0.47e1.46)
[0.524]
0.85 (0.45e1.60)
[0.616]
No. of cases dropped due to
missing values
0 30 No. of cases dropped due to
missing values
0 11
a Adjustment using propensity score for age, sex, initial AAA diameter, FEV1, log(creatinine), statin use, shape of graft, aneurysm top
neck diameter, aneurysm bottom neck diameter, aneurysm neck length, right common iliac diameter, left common iliac diameter and
calendar year of operation.
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285A Comparison of Zenith and Talent Grafts in the UK EVAR TrialsTable 3. Reasons for secondary intervention in the EVAR trials
Complication EVAR trial 1 EVAR trial 2
Zenith N¼ 318
(% of 318)
Talent N¼ 187
(% of 187)
Total
N¼ 505
Zenith N¼ 109
(% of 109)
Talent N¼ 34
(% of 34)
Total
N¼ 143
Graft rupture 5 (1.6%) 2 (1.1%) 7 0 0 0
Graft infection 1 (0.3%) 0 1 0 0 0
Migration 2 (0.6%) 5 (2.7%) 7 0 0 0
Type 1 endoleak (proximal or distal) 8 (2.5%) 9 (4.8%) 17 5 (4.6%) 1 (2.9%) 6
Type 3 endoleak 5 (1.6%) 0 5 3 (2.8%) 1 (2.9%) 4
Graft kinking 0 1 (0.5%) 1 1 (0.9%) 0 1
Endotension 0 0 0 0 1 (2.9%) 1
Type 2 endoleak 8 (2.5%) 7 (3.7%) 15 4 (3.7%) 0 4
Technical deployment problems 7 (2.2%) 2 (1.1%) 9 0 0 0
Unspecified endoleak 2 (0.6%) 3 (1.6%) 5 0 2 (5.9%) 2
Graft thrombosis 11 (3.5%) 2 (1.1%) 13 1 (0.9%) 1 (2.9%) 2
Graft stenosis 1 (0.3%) 0 1 0 0 0
Distal embolisation from graft 1 (0.3%) 0 1 0 0 0
Anastomotic aneurysm 0 1 (0.5%) 1 0 0 0
Iliac expansion 0 1 (0.5%) 1 0 0 0
Other surgery during primary admission
(cardiac/abdominal or vascular)
5 (1.6%) 7 (3.7%) 12 5 (4.6%) 2 (5.9%) 7
Other and unknown 0 2 (1.1%) 2 2 (1.8%) 2 (5.9%) 4
Total 56 (17.6%) 42 (22.5%) 98 21 (19.3%) 10 (29.4%) 31there were fewer secondary interventions in patients
with Zenith grafts (19.3%) versus patients with Talent
grafts (29.4%). The secondary intervention rate for the
Zenith and Talent groups combined in EVAR 2 (10.9
per 100 person years) was higher than that for the pa-
tients in EVAR 1 (7.2 per 100 person years), but this
did not achieve statistical significance, hazard ratio
1.33 [95% CI 0.89e2.00] and there are many differ-
ences in baseline characteristics of patients between
the two trials that could contribute to this observation.
The crude all-cause mortality was much higher thanin EVAR 1, but there were no significant differences
between the Talent and Zenith patients in terms of ei-
ther AAA-related or all-cause mortality (Table 2). Ad-
justed survival curves for secondary interventions
and mortality are shown in Figs. 3 and 4 respectively.
Combining EVAR 1 and EVAR 2
The number of secondary interventions and AAA-
related deaths in each group was small. So to improve
the power of the analysis, despite the very differentFig. 1. EVAR 1 adjusted Cox regression estimates of time to secondary intervention by device graft used with numbers
at risk.
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286 The EVAR Trial ParticipantsFig. 2. EVAR 1 adjusted Cox regression survival estimates by device graft used with numbers at risk.co-morbidities of patients in the two trials, the device
differences were combined across trials (Table 5).
There were no significant differences in secondary
intervention rate, AAA-related mortality or all-cause
mortality although the direction of results tended to
favour the patients with Zenith devices.
Discussion
The two principal endografts used in the EVAR trials
have different design features. Talent is a modular
polyester graft with interspersed self-expanding
stents. It is available in aortic diameters ranging
from 24e36 mm and employs a non barbed supra-
renal bare metal fixation. Zenith is a self-expanding
modular Dacron graft supported by Z stents. It also
uses suprarenal bare metal fixation, but unlike with
the the Talent device, proximal fixation is assisted
by barbs which can be driven into the aortic wall us-
ing a balloon moulding technique. This is marketed as
producing a very low rate of proximal graft migra-
tion. Likewise, it is available in a variety of diameters
ranging between 22 and 36 mm, although the larger
diameters have only been available latterly. Both
devices have iliac limb diameters varying from
8e24 mm and both have additional components,
such as proximal cuffs and extension limbs, which
are used as required to generate an adequate seal at
the time of or following initial deployment. In
addition, the Zenith device can now be obtained in
Eur J Vasc Endovasc Surg Vol 34, September 2007scalloped or fenestrated modalities, although these
devices were not available for inclusion in either the
EVAR 1 or 2 trials.
The term Talent or Zenith graft is used overall,
even though there have been design modifications
during the recruitment period to the EVAR trials
(1999e2004). The criteria for secondary interventions
were not pre-specified and indeed may have altered
during the trials, with fewer secondary interventions
for type II endoleak in the latter part of the trial.
The non-randomised comparison of these two devices
for AAA repair is subject to potential bias and there-
fore comparative data have been adjusted for multiple
confounders, including calendar year of operation to
allow for device modification. Only mid-term results
are available. For all these reasons the results must
be interpreted with caution.
Although the crude AAA-related and all-cause
mortalities were higher for patients with Talent grafts,
this could be explained by the Talent patients being
less fit than Zenith patients, especially with respect
to lung function in EVAR Trial 1; in particular there
is a suspicion that the shorter operating time for
Talent devices could be a contributory factor to the in-
creased use of these devices in patients with poor
lung function. After adjustment for co-morbidities
there was no clear difference in all-cause mortality
between patients with Talent and Zenith devices.
A small amount of missing data resulted in loss of
up to 41 patients in the adjusted analyses. There
were not a disproportionate number of secondary
287A Comparison of Zenith and Talent Grafts in the UK EVAR TrialsTable 4. Baseline demographic and peri-operative variables for patients in EVAR 2 with elective endovascular repair by device type
Zenith (N¼ 109) Talent (N¼ 34) P-value
Mean (s.d.) Mean (s.d.) Student’s t-test
Continuous variables
Age at randomisation (years) 77.3 (6.8) 75.4 (6.1) 0.15
AAA diameter (cm) 6.8 (1.1) 6.8 (1.1) 0.84
FEV1 (L) 1.6 (0.6) 1.6 (0.6) 0.49
Creatinine, median [IQR] (mmol/L)
(Median used as data skewed)
105 [87e123] 111 [88e134] 0.86a
AAA top neck diameter (cm) 2.4 (0.3) 2.4 (0.4) 0.28
AAA lower neck diameter (cm) 2.6 (0.3) 2.5 (0.5) 0.37
AAA neck length (cm) 2.8 (1.5) 2.8 (1.0) 0.88
Right common iliac diameter (cm) 1.7 (0.6) 2.1 (1.5) 0.09
Left common iliac diameter (cm) 1.6 (0.6) 1.6 (0.7) 0.52
Body mass index (kg/m2) 26.9 (5.0) 26.8 (4.6) 0.99
Systolic blood pressure (mm Hg) 139.5 (21.1) 140.5 (17.5) 0.81
Serum cholesterol (mmol/L) 4.7 (1.0) 4.8 (1.7) 0.71
Calendar date of operation
(years since 01.01.1998)
5.0 (1.3) 4.8 (1.4) 0.27
No. of patients (%) No. of patients (%) Chi-squared test
Categorical variables
Sex
Number of men 98 (89.9%) 28 (82.4%) 0.24
Statin used 46 (42.2%) 20 (58.8%) 0.09
Smoking status
Current 25 (22.9%) 2 (5.9%) 0.19
Past 76 (69.7%) 31 (91.2%)
Never 8 (7.3%) 1 (2.9%)
Mean (s.d) Mean (s.d) Student’s t-test
Peri-operative continuous variables
Blood loss (mls) 171 (643) 277 (461) 0.38
Contrast agent (mls) 203 (110) 174 (101) 0.21
Length of operation (mins) 194 (58) 192 (72) 0.82
ITUþHDU usage (days) 1.7 (3.3) 1.7 (3.2) 0.92
Length hospital stay (days) 11.4 (19.2) 14.8 (11.2) 0.33
No. of patients (%) No. of patients (%) Chi-squared test
Peri-operative categorical variables
Shape of the graft
Uni-iliac 7 (6.4%) 7 (21.9%) 0.01
Bi-iliac/bi-fem 102 (93.6%) 25 (78.1%)
Anaesthesia
General 59 (55%) 14 (45%) 0.35
Epidural/local 49 (45%) 17 (55%)
a Student’s t-test based upon log-transformed creatinine measurements.
FEV1¼ Forced expiratory volume in 1 sec, ITU¼ Intensive Care Unit, HDU¼High Dependency Unit.interventions or deaths in the patients excluded with
missing data and hence missing data are not likely
to be an important source of bias. In addition there
did not appear to be any significant centre effect on
any of the outcome measures. As expected, both
AAA-related and all-cause mortality were higher in
EVAR 2 patients.
There was a non-significant trend for patients with
Zenith endografts to have a lower secondary interven-
tion rate than patients with Talent endografts; 6.4 ver-
sus 8.6 per 100 patient-years respectively for EVAR 1
patients. It must be stated however that this study
was not powered to detect small differences insecondary intervention rates. Nevertheless, the direc-
tion of benefit in favour of Zenith is in accord with
other studies, although usually secondary interven-
tions are reported as crude percentages, which tend
to underestimate the secondary intervention rate.
For instance, in the EUROSTAR registry 91/1147
(7.9%) patients with Zenith grafts had secondary in-
terventions compared with 77/791 (9.7%) patients
with Talent grafts.7 In a much smaller Spanish study,
the secondary intervention rate for patients with
Zenith and Talent grafts were 1.7% and 11.1% res-
pectively.15 In contrast to these observations, it has
been suggested that patients with Talent grafts mightEur J Vasc Endovasc Surg Vol 34, September 2007
288 The EVAR Trial ParticipantsFig. 3. EVAR 2 adjusted Cox regression estimates of time to secondary intervention by device graft used with numbers at risk.have the lowest rate of type II endoleaks.6 However,
there was no evidence of fewer interventions for
type II endoleaks in patients with Talent grafts in
the EVAR trials. Previously, the range of Talent grafts
available made them applicable to wider necked an-
eurysms than the Zenith graft, but again there was
no clear evidence that Talent grafts were used in cases
with wider aneurysm necks in the EVAR trials. The
softer Talent graft may have been preferred to treatpatients with significant angulation of their infrarenal
necks. In this group, deployment of the stiffer Zenith
device with the rigid suprarenal uncovered stent
could result in proximal type 1 endoleak. Likewise,
the Zenith graft with its long suprarenal barbs may
have been used preferentially by several centres for
the treatment of patients with ‘‘short’’ infrarenal aortic
necks (0.5e1.5 mm), in an attempt to minimise the
risk of proximal graft migration. Again, there is noFig. 4. EVAR 2 adjusted Cox regression survival estimates by device graft used with numbers at risk.
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vise the use of scalloped or fenestrated grafts for these
patients. Another factor favouring the use of the
Zenith device was the superiority of its delivery sys-
tem. Whereas the Zenith consisted of a low profile
rigid delivery system and utilised a long tapered
nose cone, the Talent delivery system was designed
with a shorter, stubbier nose cone and a softer outer
sheath, which often deformed like a concertina during
more difficult deployments. This has been corrected
with current devices and the two delivery systems
are now very similar. Despite these differences, the
major determinant of graft usage is likely to have
been ‘centre directed’, with individual endovascular
specialists preferring a single favourite device for
their patients. In fact, many centres used a single
device type during the course of the trials, hence the
importance of adjusting for centre.
The results presented here are the first device-
specific analyses based upon the EVAR Trials and
the outcomes analysed were selected because they
are relatively robust endpoints that do not require fur-
ther validation. Although no statistically significant
differences have been noted in the performance of
each graft, the follow-up period is relatively short
(mean 3.8 years, not accounting for deaths) and it is
possible that the performance of these devices may
not demonstrate such equivalence with continued
follow-up. Equally it is possible that any difference
in secondary intervention rate would be revealed
early, during the time period with the highest rate of
secondary intervention. It is also worth noting that
Table 5. Cox regression analysis for secondary intervention, AAA-
related mortality, and all-cause mortality for patients with Zenith
versus Talent devices in EVAR 1 and 2 combined
No. events/No. patients
(Events per 100 person-years)
Hazard ratioa (95% CI) [p-value]
Zenith
(N¼ 427)
Talent
(N¼ 221)
Crude Adjustedb
Secondary intervention
77/427 (7.0) 52/221 (9.4) 0.75 (0.53e1.07)
[0.116]
0.77 (0.52e1.12)
[0.174]
AAA-related mortality
15/427 (1.2) 9/221 (1.4) 0.74 (0.32e1.71)
[0.480]
0.90 (0.37e2.19)
[0.816]
All-cause mortality
104/427 (8.5) 68/221 (10.3) 0.74 (0.54e1.01)
[0.056]
0.81 (0.58e1.14)
[0.224]
No. of cases dropped due to
missing value
0 41
a Hazard ratio stratified by trial.
b Adjustment using propensity score for age, sex, initial AAA di-
ameter, FEV1, log(creatinine), statin use, shape of graft, aneurysm
top neck diameter, aneurysm bottom neck diameter, aneurysm
neck length, right common iliac diameter, left common iliac diame-
ter and calendar year of operation.although the Excluder device results appear encour-
aging, they are based on very small numbers and
should be interpreted with caution. For this reason,
it is imperative that comparisons between devices in
terms of both AAA and all-cause mortality, in addi-
tion to specific complications such as graft rupture,
migration and endoleak, continue. Recently, the
EVAR Trials Management Committee have secured
further funding for the instigation of a central CT
scan core laboratory which will be used to validate
all the CT scan measurements as well as any reports
of device related complications. As the reporting of
these events is subject to individual interpretation,
the data will need to be validated before a reliable
comparison can be made. This will become a useful
tool for monitoring and investigating the performance
of these devices further.
In summary, the current data suggests that both
Zenith and Talent endografts performed well within
the context of the EVAR 1 and 2 trials, as depicted
by a low AAA-related and all-cause mortality. Al-
though no significant difference was detected in the
performance of these devices, there remains the possi-
bility that the secondary intervention rate may be
higher for patients with Talent grafts.
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